ArticlePharmaceuticals (Basel, Switzerland)2024
The Potential Therapeutic Use of Agarwood for Diabetes: A Scoping Review.
Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- AdipoRon's Impact on Alzheimer's Disease-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Prospective longitudinal study of dynamic depressive symptom trajectories and diabetes onset risk in older adults: a 10-year follow-up of the HRS and ELSA cohorts.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn 2019, 9.3% (463 million) of adults worldwide had diabetes, according to the International Diabetes Federation (IDF). By 2030, the number will rise to 10.2% (578 million) and 10.9% (700 million) by 2045 if effective prevention methods are not implemented. Agarwood is a pathological product and valuable plant due to its numerous medicinal properties, and it is used as an essential ingredient in medicine. Therefore, we conducted this review to determine agarwood's potential health benefit effect on type 2 diabetes. RESULTS AND DISCUSSION: Although no clinical trials were found, the evidence from in vitro and in vivo studies is promising. Agarwood has shown the ability to reduce the activity of α-glucosidase, α-amylase, and lipase, promote adiponectin secretion during adipogenesis, and reduce oxidative stress. Animal studies elucidated hypoglycaemic, antidyslipidemia, anti-obesity, and organ protective effects from agarwood. MATERIALS AND
methodsOriginal articles were searched in three databases (PubMed, Scopus, and Cochrane Library) using the medical subject heading (MeSH) term "diabetes" crossed with the term "agarwood" from 2008 to 2024. Synonyms and relevant search terms were also searched.
conclusionsThis effect underscores the need for further research and the potential for groundbreaking discoveries in the field of diabetes treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.